A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...

Every January, millions of people start the new year vowing to lose weight. But in 2025, many of those hoping to shed the ...

In a world where weight loss and fitness take center stage, numerous products vie for attention, each promising remarkable ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

Most  investors make a New Year's resolution to revamp their portfolio. But, in 2025, an unusual amount of uncertainty ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...